Oxacillin for Injection Recalled Nationwide for Lack of Sterility Assurance
Sagent Pharmaceuticals is recalling Oxacillin for Injection due to lack of assurance of sterility. The product was distributed to healthcare facilities nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for an injectable antibiotic with lack of assurance of sterility. While no illnesses or injuries have been reported, the lack of sterility assurance in an intravenous product poses a potential risk of serious infection, elevating it above moderate severity despite the absence of confirmed harm.
Plain-English summary
Sagent Pharmaceuticals is recalling Oxacillin for Injection, USP (10 gram pharmacy bulk package bottles) nationwide due to lack of assurance of sterility. The product was distributed to healthcare facilities across the United States.
Oxacillin is an antibiotic administered intravenously. The lack of assurance of sterility in an injectable product poses a potential risk of serious infection to patients.
Affected lots are OXT202, OXT203, and OXT301 (distributed under NDC 25021-163-99) and OXT205 and OXT204 (distributed under novaplus NDC 25021-163-68). Healthcare facilities that received this product should quarantine affected inventory and consult appropriate clinical and pharmacy personnel regarding patients who may have been treated with these affected lots.
The recalled product
- Product
- Oxacillin for Injection, USP, 10 gram per pharmacy Bulk Package bottle, For Intravenous Use, Rx only, packaged as a) NDC 25021-163-99 and b) novaplus NDC 25021-163-68, Mfd. for SAGENT Pharmaceuticals, Schaumburg, IL 60195. Made in India.
- Manufacturer
- Sagent Pharmaceuticals
- Category
- Drug — Injectable Antibiotic
- Hazard
- lack-of-sterility
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot: a) OXT202
- exp 5/31/2025
- OXT203
- OXT301
- exp 12/31/2025
- b) OXT205
- exp 6/30/2025
- OXT204
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27